Crossmark

Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer

Crossref DOI link: https://doi.org/10.1186/s12885-018-4055-9

Published Online: 2018-02-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Prokopchuk, Olga http://orcid.org/0000-0002-0697-512X
Grünwald, Barbara

Nitsche, Ulrich

Jäger, Carsten

Prokopchuk, Oleksii L.

Schubert, Elaine C.

Friess, Helmut

Martignoni, Marc E.

Krüger, Achim
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (KR2047/1-2, KR2047/1-3, KR2047/3-1)

European Union Seventh Framework Programme ((FP7/2007-2013 n°263307)

Wilhelm-Sander-Stiftung (2016.124.1)
More Information

Article History

Received: 28 November 2016

Accepted: 25 January 2018

First Online: 2 February 2018

Ethics approval and consent to participate

: The clinical and laboratory data could be used only after the consent of the patient to other scientific purposes. An Institutional Review Board „Ethikkommission der Technischen Universität München “approved the study (Nr. 1946/07). Written informed consent was obtained from the human subjects.

: Not applicable.

: The authors have declared no conflicts of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below